Celon Pharma at ESMO 2018
Representatives of the Oncology Research Group will take part in ESMO 2018, a congress organised by the European Society for Medical Oncology, which will be held on 19 October in Munich.
In the course of the congress, they will present selected results of preclinical trials for the FGFR inhibitor at a poster session held on 21 October.
The poster title is: The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy.